ALPN-202 – NEON-1 (Alpine Immune Sciences)
Description: An open-Label Study of ALPN-202 In Subjects With Advanced Malignancies (NEON-1)
Mechanism of Action: Inhibits PDL1 and CTLA4, engages CD28 co-stimulator.
Target Patient Population: Currently in expansion for Melanoma, Renal cell and PDL1 positive cancers only
Study Design: Study drug is administered IV every 1 or 3 weeks